TY - JOUR
T1 - Use of PEG-asparaginase in a case of Hepatosplenic γδ T-cell lymphoma with long-term remission after stem cell transplantation
AU - Sun, Kai
AU - Sanchez, Cesar Gentille
AU - Pingali, Sai Ravi
AU - Iyer, Swaminathan
N1 - Publisher Copyright:
© 2018 the authors.
PY - 2018/9/20
Y1 - 2018/9/20
N2 - Hepatosplenic γδ T-cell lymphoma (HSTCL) is a rare aggressive peripheral T-cell lymphoma. Prognosis is usually poor with a median survival between 8 and 16 months after traditional chemotherapy. Stem cell transplantation (SCT) is promising and with a more intense induction regimen, has yielded positive results. We report the use of pegylated-asparaginase (PEG-asparaginase) along with a conventional anthracycline-containing regimen in a 51-year-old male who was diagnosed with HSTCL, achieved a complete remission, and subsequently underwent peripheral blood SCT and remained in remission at the time of this case report.
AB - Hepatosplenic γδ T-cell lymphoma (HSTCL) is a rare aggressive peripheral T-cell lymphoma. Prognosis is usually poor with a median survival between 8 and 16 months after traditional chemotherapy. Stem cell transplantation (SCT) is promising and with a more intense induction regimen, has yielded positive results. We report the use of pegylated-asparaginase (PEG-asparaginase) along with a conventional anthracycline-containing regimen in a 51-year-old male who was diagnosed with HSTCL, achieved a complete remission, and subsequently underwent peripheral blood SCT and remained in remission at the time of this case report.
KW - Hepatosplenic γδ T-cell lymphoma
KW - Pegylated-asparaginase
KW - Stem cell transplant
UR - http://www.scopus.com/inward/record.url?scp=85055288921&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055288921&partnerID=8YFLogxK
U2 - 10.3332/ecancer.2018.872
DO - 10.3332/ecancer.2018.872
M3 - Article
C2 - 30483352
AN - SCOPUS:85055288921
SN - 1754-6605
VL - 12
JO - ecancermedicalscience
JF - ecancermedicalscience
M1 - 872
ER -